title: 18F-FDG PET of common enhancing malignant brain tumors.
abstract: OBJECTIVE
  The purpose of our study was to determine whether (18)F-FDG PET can be used to differentiate among common enhancing brain tumors such as lymphoma, high-grade glioma, and metastatic brain tumor.
  
  
  METHODS
  We evaluated 34 patients with an enhancing brain tumor on MRI, including seven lymphomas, nine high-grade gliomas, and 18 metastatic tumors. All patients also underwent FDG PET. For PET image analysis, regions of interest were placed over the tumor (T), contralateral cortex (C), and white matter (WM). Average and maximum pixel values were determined at each site. On the basis of these measurements, average and maximum standard uptake values (SUV(avg) and SUV(max)) were calculated, along with activity ratios (T/C(avg), T/WM(avg), T/WM(max), and T/C(max)), and comparisons among lesions were then made.
  
  
  RESULTS
  All parameters were significantly higher for lymphoma than for other tumors (p < 0.01). High-grade gliomas showed significantly higher SUV(avg) and SUV(max) than metastatic tumors (p < 0.05). Other parameters did not differ between lesion types. SUV(max) was the most accurate parameter for distinguishing lymphomas. Using an SUV(max) of 15.0 as a cutoff for diagnosing CNS lymphoma, only one high-grade glioma was found as a false-positive (SUV(max), 18.8).
  
  
  CONCLUSIONS
  FDG PET may be useful for differentiating common enhancing malignant brain tumors, particularly lymphoma versus high-grade glioma and metastatic tumor. FDG PET can provide useful information for distinguishing between lymphoma and other malignant enhancing brain tumors and is recommended when differential diagnoses are difficult to narrow using MRI alone.
authors.affiliation: Department of Radiology, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193, Japan. nkosaka@u-fukui.ac.jp
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kosaka
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Tsuchida
authors.forename: Hidemasa
authors.initials: H
authors.lastname: Uematsu
authors.forename: Hirohiko
authors.initials: H
authors.lastname: Kimura
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Okazawa
authors.forename: Harumi
authors.initials: H
authors.lastname: Itoh
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D001932:Brain Neoplasms / Q000000981:diagnostic imaging*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18